drugset / Trial / NCT01596751
Phase Ib/II Study of PLX 3397 and Eribulin in Patients With Metastatic Breast Cancer
Phase 1/2
Completed
67 enrolled
Hope Rugo, MD
Plexxikon · collabSusan G. Komen Breast Cancer Foundation · collab
Non-randomizedSequentialOpen-labelTreatment
Summary
The purpose of the Phase 1b portion of the study is to determine the best dose of PLX3397 when given in combination with standard dose eribulin (Halaven™). The purpose of the Phase 2 portion of the study is to find out what effects, good and/or bad, these drugs have on patients and their metastatic breast cancer.
Timeline
- Start
- 2012-07-12
- Primary completion
- 2017-07-05
- Completion
- 2019-07-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Eribulin | Small molecule | 1.4 mg/m2 | Intravenous |
| Subject | Pexidartinib | Small molecule | 600 mg | Oral |
| Subject | Pexidartinib | Small molecule | 800 mg | Oral |
| Subject | Pexidartinib | Small molecule | 1000 mg | Oral |